Evaluating Autologous Hair Follicle Secretome Combined With Platelet-Rich Plasma to Support Ovarian Function in Women With Premature Ovarian Insufficiency

What This Trial Is About

Researchers are studying women aged 25 to 40 with premature ovarian insufficiency POI, a condition where ovarian function declines early, causing irregular or absent periods and difficulty conceiving. This pilot study evaluates changes in ovarian function after treatment with a combination of autologous hair follicle-derived mesenchymal stem cell secretome and platelet-rich plasma PRP. The aim is to gather preliminary data on ovarian response, feasibility, and safety to guide future research. Participants receive a treatment prepared from their own hair follicles and blood. The secretome and PRP mixture is injected into the pelvic cul-de-sac using transvaginal ultrasound guidance, avoiding direct ovarian injection. If ovarian response is insufficient after about three months, an additional injection may be offered. The study does not include a placebo or control group. Throughout the study, participants will have blood tests and ultrasounds to monitor hormone levels and antral follicle count, assessing ovarian function changes. Researchers will also track menstrual function, ovulation, and pregnancy outcomes, including spontaneous pregnancies and pregnancies after fertility treatment, with follow-up lasting up to a year after treatment. This exploratory study helps understand potential benefits and informs future trials.

Autologous Hair Follicle-Derived Secretome and Platelet-Rich Plasma for Premature Ovarian Insufficiency